Sinisa Savic1, Laura J Dickie, Michele Battellino, Michael F McDermott. 1. Department of Clinical Immunology, NIHR-Leeds Musculoskeletal Biomedical Research Unit (NIHR-LMBRU), Leeds Institute of Molecular Medicine, St. James's University Hospital, Leeds, UK.
Abstract
PURPOSE OF REVIEW: The spectrum of periodic fever syndromes (PFS)/autoinflammation diseases is continuously expanding. This review provides an overview of the primary research and an update on the main clinical developments in these disorders published in the past 12-18 months. RECENT FINDINGS: IL-1β is pivotal to the pathogenesis of most of the PFS. In familial Mediterranean fever (FMF) MEFV mutations lead to gain of pyrin function, resulting in inappropriate IL-1β release that is dependent on ASC but not the NLRP3 inflammasome. Anti-IL-1 therapy is effective in tumour necrosis factor receptor-associated periodic syndrome (TRAPS), whilst both spontaneous and pathogen-associated molecular patterns (PAMPs) induced IL-1β release have been demonstrated in NLRP12-associated periodic syndrome (NAPS12). Somatic NLRP3/CIAS1 mosaicism is a significant cause of cryopyrin-associated periodic syndromes (CAPS). Close connections have also been established between metabolic and inflammatory pathways. In TRAPS increased reactive oxygen species (ROS) of mitochondrial origin leads to production of pro-inflammatory cytokines, whilst NLRP3 inflammasome activation in type 2 diabetes (T2D) is induced by oligomers of islet amyloid polypeptides (IAPP). SUMMARY: Caspase 1 activation and IL-1β release is central to the pathogenesis of many autoinflammatory syndromes. This is supported by the effectiveness of anti-IL-1 biologics in treatment of these disorders.
PURPOSE OF REVIEW: The spectrum of periodic fever syndromes (PFS)/autoinflammation diseases is continuously expanding. This review provides an overview of the primary research and an update on the main clinical developments in these disorders published in the past 12-18 months. RECENT FINDINGS: IL-1β is pivotal to the pathogenesis of most of the PFS. In familial Mediterranean fever (FMF) MEFV mutations lead to gain of pyrin function, resulting in inappropriate IL-1β release that is dependent on ASC but not the NLRP3 inflammasome. Anti-IL-1 therapy is effective in tumour necrosis factor receptor-associated periodic syndrome (TRAPS), whilst both spontaneous and pathogen-associated molecular patterns (PAMPs) induced IL-1β release have been demonstrated in NLRP12-associated periodic syndrome (NAPS12). Somatic NLRP3/CIAS1 mosaicism is a significant cause of cryopyrin-associated periodic syndromes (CAPS). Close connections have also been established between metabolic and inflammatory pathways. In TRAPS increased reactive oxygen species (ROS) of mitochondrial origin leads to production of pro-inflammatory cytokines, whilst NLRP3 inflammasome activation in type 2 diabetes (T2D) is induced by oligomers of islet amyloid polypeptides (IAPP). SUMMARY:Caspase 1 activation and IL-1β release is central to the pathogenesis of many autoinflammatory syndromes. This is supported by the effectiveness of anti-IL-1 biologics in treatment of these disorders.
Authors: S Bens; T Zichner; A M Stütz; A Caliebe; R Wagener; K Hoff; J O Korbel; P von Bismarck; R Siebert Journal: Genes Immun Date: 2014-01-23 Impact factor: 2.676
Authors: Hella Luksch; Stefan Winkler; Michael C Heymann; Felix Schulze; Sigrun R Hofmann; Joachim Roesler; Angela Rösen-Wolff Journal: Curr Rheumatol Rep Date: 2015-07 Impact factor: 4.592
Authors: Anna Simon; Joost P H Drenth; Dietrich Matern; Eric S Goetzman; Elizabeth J Hager; K Michael Gibson Journal: Mol Genet Metab Date: 2013-01-15 Impact factor: 4.797
Authors: Dennis C Ko; Eric R Gamazon; Kajal P Shukla; Richard A Pfuetzner; Dale Whittington; Tarah D Holden; Mitchell J Brittnacher; Christine Fong; Matthew Radey; Cassandra Ogohara; Amy L Stark; Joshua M Akey; M Eileen Dolan; Mark M Wurfel; Samuel I Miller Journal: Proc Natl Acad Sci U S A Date: 2012-07-25 Impact factor: 11.205